WO2016075546A3 - Antibodies that neutralize ebola virus and uses thereof - Google Patents

Antibodies that neutralize ebola virus and uses thereof Download PDF

Info

Publication number
WO2016075546A3
WO2016075546A3 PCT/IB2015/002342 IB2015002342W WO2016075546A3 WO 2016075546 A3 WO2016075546 A3 WO 2016075546A3 IB 2015002342 W IB2015002342 W IB 2015002342W WO 2016075546 A3 WO2016075546 A3 WO 2016075546A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
ebola virus
relates
antigen binding
well
Prior art date
Application number
PCT/IB2015/002342
Other languages
French (fr)
Other versions
WO2016075546A2 (en
Inventor
Antonio Lanzavecchia
Davide Corti
Original Assignee
Antonio Lanzavecchia
Davide Corti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antonio Lanzavecchia, Davide Corti filed Critical Antonio Lanzavecchia
Publication of WO2016075546A2 publication Critical patent/WO2016075546A2/en
Publication of WO2016075546A3 publication Critical patent/WO2016075546A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention relates to antibodies, and antigen binding fragments thereof, that specifically bind to the Ebola virus GP protein or neutralize infection of Ebola virus. The invention also relates to antigenic sites to which the antibodies and antigen binding fragments bind, as well as to nucleic acids that encode, and immortalized B cells and cultured plasma cells that produce, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and polypeptides recognized by the antibodies of the invention in screening methods as well as in the diagnosis, treatment and prevention of Ebola virus infection.
PCT/IB2015/002342 2014-11-14 2015-11-13 Antibodies that neutralize ebola virus and uses thereof WO2016075546A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462080094P 2014-11-14 2014-11-14
US62/080,094 2014-11-14

Publications (2)

Publication Number Publication Date
WO2016075546A2 WO2016075546A2 (en) 2016-05-19
WO2016075546A3 true WO2016075546A3 (en) 2016-06-30

Family

ID=55262840

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2015/002342 WO2016075546A2 (en) 2014-11-14 2015-11-13 Antibodies that neutralize ebola virus and uses thereof

Country Status (1)

Country Link
WO (1) WO2016075546A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3875481A1 (en) 2014-11-14 2021-09-08 The U.S.A. as represented by the Secretary, Department of Health and Human Services Neutralizing antibodies to ebola virus glycoprotein and their use
WO2018017964A2 (en) * 2016-07-21 2018-01-25 Emory University Ebola virus antibodies and binding agents derived therefrom
WO2019136029A1 (en) * 2018-01-02 2019-07-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to ebola virus glycoprotein and their use
CN111690056B (en) * 2020-04-30 2021-12-21 清华大学 Monoclonal antibody for neutralizing EB virus and application thereof
WO2023201333A1 (en) * 2022-04-14 2023-10-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bispecific antibodies to ebola virus glycoprotein and their use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004018649A2 (en) * 2002-08-23 2004-03-04 United States Army Medical Research Institute Of Infectious Diseases Monoclonal antibodies and complementarity-determining regions binding to ebola glycoprotein
WO2011071574A2 (en) * 2009-09-02 2011-06-16 United States Deparment Of The Army, As Represented By The Secretary Of The Army Monoclonal antibodies against glycoprotein of ebola sudan boniface virus

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (en) 1971-02-10 1977-09-15 Organon Nv METHOD FOR THE DETERMINATION AND DETERMINATION OF SPECIFIC BINDING PROTEINS AND THEIR CORRESPONDING BINDABLE SUBSTANCES.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3766162A (en) 1971-08-24 1973-10-16 Hoffmann La Roche Barbituric acid antigens and antibodies specific therefor
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
JPS5896026A (en) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd Novel urokinase derivative, its preparation and thrombolytic agent containing the same
EP0098110B1 (en) 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Long-acting composition
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
AU2004215125B2 (en) 2003-02-26 2011-01-06 Institute For Research In Biomedicine Monoclonal antibody production by EBV transformation of B cells
DK2350128T3 (en) 2008-10-22 2014-12-01 Inst Research In Biomedicine Methods for producing antibodies from plasma cells

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004018649A2 (en) * 2002-08-23 2004-03-04 United States Army Medical Research Institute Of Infectious Diseases Monoclonal antibodies and complementarity-determining regions binding to ebola glycoprotein
WO2011071574A2 (en) * 2009-09-02 2011-06-16 United States Deparment Of The Army, As Represented By The Secretary Of The Army Monoclonal antibodies against glycoprotein of ebola sudan boniface virus

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LEE J E ET AL: "Neutralizing ebolavirus: structural insights into the envelope glycoprotein and antibodies targeted against it", CURRENT OPINION IN STRUCTURAL BIOLOGY, ELSEVIER LTD, GB, vol. 19, no. 4, 1 August 2009 (2009-08-01), pages 408 - 417, XP026541929, ISSN: 0959-440X, [retrieved on 20090624], DOI: 10.1016/J.SBI.2009.05.004 *
XIANGGUO QIU ET AL: "Characterization ofglycoprotein-specific monoclonal antibodies", CLINICAL IMMUNOLOGY, ACADEMIC PRESS, US, vol. 141, no. 2, 13 August 2011 (2011-08-13), pages 218 - 227, XP028322702, ISSN: 1521-6616, [retrieved on 20110831], DOI: 10.1016/J.CLIM.2011.08.008 *

Also Published As

Publication number Publication date
WO2016075546A2 (en) 2016-05-19

Similar Documents

Publication Publication Date Title
AU2017297757A1 (en) Novel antibodies specifically binding to zika virus epitopes and uses thereof
PH12018502478A1 (en) Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen
WO2016154003A8 (en) Neutralizing antibodies to gp120 and their use
WO2016196975A8 (en) Neutralizing antibodies to hiv-1 env and their use
MX2019003768A (en) Hpv-specific binding molecules.
PH12017500890A1 (en) Antibody drug conjugates
WO2018017864A3 (en) Pvrig-binding agents and uses thereof
WO2016191643A3 (en) Tigit-binding agents and uses thereof
MX2021014448A (en) Modulation of stimulatory and non-stimulatory myeloid cells.
WO2015109124A3 (en) Immunomodulatory agents
AU2016320748A8 (en) Thymic stromal lymphopoietin (TSLP)-binding antibodies and methods of using the antibodies
PH12021550521A1 (en) Antibodies that potently neutralize rabies virus and other lyssaviruses and uses thereof
EP4356927A3 (en) Antibody based reagents that specifically recognize toxic oligomeric forms of tau
JO3775B1 (en) Thymic stromal lymphopoietin (tslp)-binding molecules and methods of using the molecules
WO2015197823A3 (en) Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
WO2016054598A3 (en) Antibodies that bind ebola glycoprotein and uses thereof
WO2017079479A8 (en) Neutralizing antibodies to hiv-1 gp41 and their use
MX2011000768A (en) Neutralizing anti-influenza a virus antibodies and uses thereof.
WO2011092593A3 (en) Hiv-1 neutralizing antibodies and uses thereof
WO2016173605A8 (en) Ultra-potent neutralization of cytokines by multispecific antibodies and uses thereof
WO2016075546A3 (en) Antibodies that neutralize ebola virus and uses thereof
PH12020550025A1 (en) Multispecific antibodies specifically binding to zika virus epitopes and uses thereof
WO2018194496A3 (en) Monoclonal antibody to pd-l1
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
WO2015112558A3 (en) Peptides, devices, and methods for the detection of anaplasma antibodies

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15828844

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15828844

Country of ref document: EP

Kind code of ref document: A2